Rubicon Research IPO Allotment Status Analyzed

The Rubicon Research IPO, a pharmaceutical company, is nearing its final allotment stage. The public subscription period closed on Monday, October 13, 2025, and the response was incredibly strong. Investors showed significant interest in the company’s shares, and the final allocation decisions are set to be announced soon.

Key Points

• Strong investor demand: IPO subscribed 103.9 times.
• QIBs dominated: Reserved portion subscribed 130.26 times.
• Retail investors interested: 35.47 times subscription rate.
• Allotment updates: Check BSE or MUFG Intime portals.
• GMP indicates premium: Unlisted shares traded at ₹612.
• Listing expected: Shares to list on October 16, 2025.

The National Stock Exchange (NSE) reported that the IPO was subscribed to 103.9 times, meaning investors placed bids for 1.7 billion shares, while the company offered just 16.45 million shares. Qualified Institutional Buyers (QIBs) played a key role, fully subscribing to their designated portion (130.26 times) – this shows a high level of confidence in the company’s future.

Non-Institutional Investors also showed considerable interest, subscribing at 97.61 times, and retail investors subscribed at a rate of 35.47 times. The impressive subscription rate highlights the potential of Rubicon Research and the investment opportunities it presents.

To find out if you’ve been allocated shares, you can check the official websites. The BSE (bseindia.com/investors/appli_check.aspx) and MUFG Intime India (in.mpms.mufg.com/Initial_Offer/public-issues.html) portals are the best places to get updates. You’ll need your application number or PAN to track your allotment.

Unofficial market tracking revealed that the unlisted shares of Rubicon Research were trading at ₹612 apiece, reflecting a premium of ₹127 – or 26.19 percent – compared to the IPO’s price band, which was set between ₹461 and ₹485. This premium suggests strong anticipation for the stock’s listing.

The IPO officially opened for subscriptions on Thursday, October 9, 2025, and concluded on Monday, October 13, 2025. Following the allotment process, Rubicon Research will begin transferring shares to Demat accounts on October 15, and shares will officially list on the BSE and NSE on Thursday, October 16, 2025.

MUFG Intime India is the registrar for this public issue. Axis Capital, IIFL Capital Services, JM Financial, and SBI Capital Markets are involved as lead managers to the issue. The company intends to use the funds raised primarily for debt repayment and strategic acquisitions, as outlined in the red herring prospectus (RHP).

“A successful IPO indicates strong investor faith and sets the stage for Rubicon Research’s future growth.”